title: Remyelination and multiple sclerosis: therapeutic approaches and challenges.
abstract: Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system. After acute inflammatory mediated demyelination, some remyelination often occurs, but in chronic demyelinated MS plaques, remyelination frequently fails. Chronically demyelinated axons cause a variety of symptoms and probably are more likely to degenerate, leading to irreversible clinical disability. Oligodendrocyte precursor cells (OPCs) present in the adult brain can proliferate and differentiate to remyelinate lesions. Failure of remyelination in the majority of MS patients is secondary to arrest in OPC differentiation. Many therapies have been developed to modulate the immune response in MS, but no neuroprotective or remyelinating therapies are available. Promoting remyelination is a promising avenue for protecting axons, reversing neurologic disability and preventing progressive disease in MS. This review will begin with an overview of remyelination and remyelination failure, consequences of demyelination, and available animal disease models. In addition, preclinical and clinical studies on the most promising potential therapies for inducing remyelination will be described.
authors.affiliation: Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, OR, 97239, USA.
authors.forename: Meredith D
authors.initials: MD
authors.lastname: Hartley
authors.forename: Ghadah
authors.initials: G
authors.lastname: Altowaijri
authors.forename: Dennis
authors.initials: D
authors.lastname: Bourdette
mesh_terms: D000818:Animals; D002454:Cell Differentiation; D004195:Disease Models, Animal; D006801:Humans; D009103:Multiple Sclerosis / Q000628:therapy*; D009416:Nerve Regeneration / Q000502:physiology*; D009836:Oligodendroglia / Q000502:physiology*; D020127:Recovery of Function / Q000502:physiology*; D033581:Stem Cell Transplantation
references.citation: J Mol Endocrinol. 2010 Jan;44(1):13-23
references.pmid: 19578096
references.citation: Nat Protoc. 2013 Apr;8(4):771-82
references.pmid: 23589937
references.citation: Nat Rev Neurosci. 2008 Nov;9(11):839-55
references.pmid: 18931697
references.citation: Nat Rev Neurol. 2012 Nov 5;8(11):624-34
references.pmid: 23026979
references.citation: QJM. 2014 May;107(5):335-9
references.pmid: 24368858
references.citation: Front Cell Neurosci. 2014 Mar 13;8:73
references.pmid: 24659953
references.citation: Ann Neurol. 2013 Feb;73(2):266-80
references.pmid: 23463525
references.citation: Neurology. 2009 Jun 2;72(22):1914-21
references.pmid: 19487649
references.citation: Cell Transplant. 2014;23(4-5):567-71
references.pmid: 24816451
references.citation: J Neurosci. 2008 Dec 24;28(52):14189-201
references.pmid: 19109501
references.citation: Drugs. 2013 Dec;73(18):2017-29
references.pmid: 24242317
references.citation: Glia. 2002 Mar 1;37(3):241-9
references.pmid: 11857682
references.citation: J Cell Sci. 1972 Mar;10(2):535-46
references.pmid: 5018033
references.citation: Neurosci Lett. 2009 Jun 12;456(3):112-9
references.pmid: 19429145
references.citation: J Neurosci Res. 1999 Oct 15;58(2):207-13
references.pmid: 10502277
references.citation: Nat Biotechnol. 2013 May;31(5):426-33
references.pmid: 23584611
references.citation: Curr Neurol Neurosci Rep. 2009 Sep;9(5):411-7
references.pmid: 19664372
references.citation: Neurotherapeutics. 2011 Oct;8(4):650-8
references.pmid: 21904791
references.citation: Brain Res Brain Res Rev. 2005 Sep;49(2):227-41
references.pmid: 16111552
references.citation: Front Neurosci. 2012 Feb 08;6:10
references.pmid: 22347156
references.citation: Endocrinology. 2011 Oct;152(10):3820-31
references.pmid: 21828184
references.citation: Arch Neurol. 2007 May;64(5):683-8
references.pmid: 17502467
references.citation: Brain. 2008 Jul;131(Pt 7):1749-58
references.pmid: 18515322
references.citation: J Neurobiol. 1999 Sep 15;40(4):497-512
references.pmid: 10453052
references.citation: CNS Drugs. 2013 Jul;27(7):493-503
references.pmid: 23681979
references.citation: Neurotherapeutics. 2013 Jan;10(1):44-54
references.pmid: 23070731
references.citation: Brain. 2006 Dec;129(Pt 12):3165-72
references.pmid: 16921173
references.citation: J Cell Biol. 2010 Feb 8;188(3):305-12
references.pmid: 20142420
references.citation: J Neuroendocrinol. 2011 Sep;23(9):778-90
references.pmid: 21707794
references.citation: Stem Cells. 2007 Feb;25(2):419-24
references.pmid: 17053214
references.citation: Int Rev Neurobiol. 2007;79:589-620
references.pmid: 17531860
references.citation: Annu Rev Neurosci. 2011;34:21-43
references.pmid: 21692657
references.citation: N Engl J Med. 2002 Jan 17;346(3):165-73
references.pmid: 11796850
references.citation: Cell Stem Cell. 2010 Jun 4;6(6):578-90
references.pmid: 20569695
references.citation: Nat Med. 2007 Oct;13(10):1228-33
references.pmid: 17906634
references.citation: Nat Protoc. 2007;2(5):1044-51
references.pmid: 17546009
references.citation: Heart Fail Rev. 2010 Mar;15(2):177-82
references.pmid: 19002578
references.citation: Nature. 2010 Nov 11;468(7321):244-52
references.pmid: 21068833
references.citation: Brain. 2008 Jul;131(Pt 7):1686-700
references.pmid: 18474520
references.citation: Nat Med. 2005 Sep;11(9):966-72
references.pmid: 16086023
references.citation: Nature. 2013 Oct 17;502(7471):327-332
references.pmid: 24107995
references.citation: Curr Opin Neurobiol. 2007 Oct;17(5):533-40
references.pmid: 17923405
references.citation: Brain. 2013 Jan;136(Pt 1):132-46
references.pmid: 23365095
references.citation: Nat Neurosci. 2007 Nov;10(11):1351-4
references.pmid: 17965654
references.citation: Glia. 1999 Feb 1;25(3):216-28
references.pmid: 9932868
references.citation: FASEB J. 2004 Oct;18(13):1577-9
references.pmid: 15319372
references.citation: Nat Neurosci. 2011 Jan;14(1):45-53
references.pmid: 21131950
references.citation: J Neuroinflammation. 2008 Jul 31;5:32
references.pmid: 18671877
references.citation: Glia. 2014 Nov;62(11):1905-15
references.pmid: 24446279